개인구독
소속 기관이 없으신 경우, 개인 정기구독을 하시면 저렴하게
논문을 무제한 열람 이용할 수 있어요.
지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2017.6
- 수록면
- 84 - 94 (11page)
이용수
초록· 키워드
오류제보하기
Objectives：Patients with schizophrenia have been reported to be more vulnerable to metabolic diseases than the general population. This study aimed to assess the prevalence of abnormal metabolic parameters and identify the factors of atypical antipsychotic drugs associated with these abnormalities in patients with schizophrenia taking atypical antipsychotic drugs.
Methods：A total of 161 inpatients with schizophrenia were recruited at Chuncheon National Hospital for 1 year in 2015. We collected demographic information, medication history, physical measurements, and metabolic parameters(body mass index(BMI), systolic and diastolic blood pressures, and serum total cholesterol and serum triglyceride levels) from the medical records of the patients. We categorized the patients into an abnormal metabolic parameters group and a control group and performed comparative analysis between the groups.
Results：Among the 161 inpatients, 56.5% were overweight(BMI≥25kg/m2) and 42.2% had hypertension. The prevalence of hypercholesterolemia(total cholesterol level＞200mg/dL) and hypertriglyceridemia(triglyceride level ＞150mg/dL) was 23.6% and 43.5%, respectively. Being overweight was strongly associated with higher total daily chlorpromazine-equivalent dose but not with age, sex, or antipsychotic polypharmacy.
Conclusion：Metabolic abnormalities are highly prevalent among patients with chronic schizophrenia. These results suggest that higher chlorpromazine-equivalent doses are associated with greater weight gain. Clinicians should be aware of the risk of metabolic abnormalities associated with a chlorpromazine-equivalent doses of antipsychotic drugs.
Methods：A total of 161 inpatients with schizophrenia were recruited at Chuncheon National Hospital for 1 year in 2015. We collected demographic information, medication history, physical measurements, and metabolic parameters(body mass index(BMI), systolic and diastolic blood pressures, and serum total cholesterol and serum triglyceride levels) from the medical records of the patients. We categorized the patients into an abnormal metabolic parameters group and a control group and performed comparative analysis between the groups.
Results：Among the 161 inpatients, 56.5% were overweight(BMI≥25kg/m2) and 42.2% had hypertension. The prevalence of hypercholesterolemia(total cholesterol level＞200mg/dL) and hypertriglyceridemia(triglyceride level ＞150mg/dL) was 23.6% and 43.5%, respectively. Being overweight was strongly associated with higher total daily chlorpromazine-equivalent dose but not with age, sex, or antipsychotic polypharmacy.
Conclusion：Metabolic abnormalities are highly prevalent among patients with chronic schizophrenia. These results suggest that higher chlorpromazine-equivalent doses are associated with greater weight gain. Clinicians should be aware of the risk of metabolic abnormalities associated with a chlorpromazine-equivalent doses of antipsychotic drugs.
목차
서론
대상 및 방법
결과
고찰
결론
참고문헌
참고문헌 (48)
참고문헌 신청
[학술지(정기간행물)] - Olfson M / 2015 / Premature mortality among adults with schizophrenia in the U.S / JAMA Psychiatry 72 : 1172 ~ 1181
[학술지(정기간행물)] - Expert Panel on Detection E, Treatment of High Blood Cholesterol in Adults / 2001 / Executive summary of the third report of The national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults(Adult Treatment Panel III) / JAMA 285 : 2486 ~ 2497
[학술지(정기간행물)] - McEvoy JP / 2005 / Prevalence of the metabolic syndrome in patients with schizophrenia:baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness(CATIE) schizophrenia trial and comparison with national estimates from NHANES III / Schizophr Res 80 : 19 ~ 32
[학술지(정기간행물)] - Beltrán-Sánchez H / 2013 / Prevalence and trends of metabolic syndrome in the adult U.S. population, 1999-2010 / J Am Coll Cardiol 62 : 697 ~ 703
[학술지(정기간행물)] - Hägg S / 2006 / High prevalence of the metabolic syndrome among a Swedish cohort of patients with schizophrenia / Int Clin Psychopharmacol 21 : 93 ~ 98
[학술지(정기간행물)] - Expert Panel on Detection E, Treatment of High Blood Cholesterol in Adults / 2001 / Executive summary of the third report of The national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults(Adult Treatment Panel III) / JAMA 285 : 2486 ~ 2497
[학술지(정기간행물)] - McEvoy JP / 2005 / Prevalence of the metabolic syndrome in patients with schizophrenia:baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness(CATIE) schizophrenia trial and comparison with national estimates from NHANES III / Schizophr Res 80 : 19 ~ 32
[학술지(정기간행물)] - Beltrán-Sánchez H / 2013 / Prevalence and trends of metabolic syndrome in the adult U.S. population, 1999-2010 / J Am Coll Cardiol 62 : 697 ~ 703
[학술지(정기간행물)] - Hägg S / 2006 / High prevalence of the metabolic syndrome among a Swedish cohort of patients with schizophrenia / Int Clin Psychopharmacol 21 : 93 ~ 98
함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
조현병 환자에서 항정신약물이 대사지표에 미치는 영향 조사 - 1년 추적연구
대한조현병학회지
2015 .10
-
항정신병약물에 의한 대사부작용에 대한 이론과 대처방안
신경정신의학
2019 .01
-
Quantitative Resting State Electroencephalography in Patients with Schizophrenia Spectrum Disorders Treated with Strict Monotherapy Using Atypical Antipsychotics
Clinical Psychopharmacology and Neuroscience
2021 .01
-
Metabolic Disturbances Independent of Body Mass in Patients with Schizophrenia Taking Atypical Antipsychotics
PSYCHIATRY INVESTIGATION
2015 .01
-
조현병 환자에서 비전형항정신병약물 사용시 대사지표에 미치는 영향 조사 : 3년 추적연구
대한조현병학회지
2017 .04
-
Antipsychotic Prescribing Patterns in First-episode Schizophrenia: A Five-year Comparison
Clinical Psychopharmacology and Neuroscience
2015 .01
-
조현병 환자에서 항정신병약물 유지치료 시 치료결과에 대한 연구
대한조현병학회지
2017 .10
-
조현병 약물치료의 최신 지견
대한의사협회지
2024 .02
-
항정신병약물의 생물학적 기전 최신 지견
신경정신의학
2019 .01
-
항정신병약물의 현재와 미래
신경정신의학
2019 .01
-
노인환자의 항정신병 약물 원외처방 내역에 미친 영향 요인 분석
한국임상약학회지
2021 .12
-
Evaluation of Paraoxonase, Arylesterase and Malondialdehyde Levels in Schizophrenia Patients Taking Typical, Atypical and Combined Antipsychotic Treatment
Clinical Psychopharmacology and Neuroscience
2016 .01
-
항정신병 약물의 병용요법을 사용 중인 환자들에서 아리피프라졸 장기 지속형 주사제의 효능
생물치료정신의학
2024 .10
-
‘2019 한국형 조현병 약물치료 지침서’에 따른 조현병에서 동반증상 및 부작용의 치료
대한조현병학회지
2019 .01
-
Antipsychotic Medication in Schizophrenic Patients is Associated with Higher Risks of Developing Bone Fractures and Refractures
Clinical Psychopharmacology and Neuroscience
2020 .01
-
Effectiveness in Switching from Antipsychotic Polypharmacy to Monotherapy in Patients with Schizophrenia: A Case Series
Clinical Psychopharmacology and Neuroscience
2020 .01
-
5년 동안 추적한 만성 조현병 환자에서 대사증후군의 예측인자
정신신체의학
2016 .01
-
Diabetic Ketoacidosis Associated With Second Generation Antipsychotics: A Case Study and Review of Literature
PSYCHIATRY INVESTIGATION
2024 .02
-
항정신병약물 임상의 역사와 미래
신경정신의학
2019 .01
-
Understanding of Antipsychotics in Elderly Patients with Dementia
Dementia and Neurocognitive Disorders(대한치매학회지)
2015 .01
이 논문의 저자 정보
이 논문과 함께 이용한 논문
최근 본 자료
댓글(0)
0
UCI(KEPA) : I410-ECN-0101-2018-512-000925397